FDA Approves Genzyme’s Mozobil
Product Provides Enhanced Mobilization of Stem Cells for Autologous Transplantation in Non-Hodgkin’s Lymphoma and Multiple Myeloma Patients
19-Dec-2008 -
Genzyme Corporation announced that the U.S. Food and Drug Administration has granted marketing approval for Mozobil™ (plerixafor injection), a drug intended to be used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the bloodstream for ...
bone marrow
chemotherapy
food
+7